Goldman Sachs Group Inc Allogene Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 5,503,141 shares of ALLO stock, worth $6.11 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,503,141
Previous 5,853,974
5.99%
Holding current value
$6.11 Million
Previous $8.55 Million
27.24%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding ALLO
# of Institutions
169Shares Held
162MCall Options Held
146KPut Options Held
97.1K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$20.8 Million1.28% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$18.3 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA11.2MShares$12.4 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR11.1MShares$12.3 Million3.7% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y910.5MShares$11.6 Million0.5% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $160M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...